Gilead is letting go of 34 employees at its Oceanside, California, site.
All entries for: Antiviral
November 18, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck is letting go of 204 employees from its Rahway, New Jersey location, continuing its aggressive layoff spree in recent months.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 5, 2025
Merck
Neutral Outlook
Rahway, NJ
10,001-50,000 employees
In 2022, the U.S. Congress passed the Inflation Reduction Act (IRA), which made significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits (which has taken effect in 2025), and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028).
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
November 5, 2025
Vir Biotechnology, Inc
Neutral Outlook
San Francisco, CA
201-500 employees
It is currently unclear how certain new measures, including the drug pricing provisions of the Inflation Reduction Act of 2022 (and subsequent rulemaking) and changes to Medicaid eligibility requirements in the OBBBA, will ultimately be effectuated. Accordingly, we cannot predict with certainty what impact these or any other federal or state health reforms will have on us, including whether finalized rules will be implemented or withstand judicial review.
Disease Area: Antiviral, Chronic Disease, Immune Diseases, Infectious Diseases, Oncology
Drug Type: Biologic
September 12, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck will terminate research and discovery efforts in the U.K., a move that includes pulling out of the Francis Crick Institute and the London BioScience Innovation Center, which will leave 125 employees jobless. The pharma giant is also pulling the plug on a roughly $1.3 billion construction project that was expected to open 120 posts for researchers and technicians. A company spokesperson said the moves reflect “the challenges of the U.K. not making meaningful progress towards addressing the lack of investment in the life science industry.” Successive U.K. governments, the spokesperson continued, have also demonstrated an “overall undervaluation of innovative medicines and vaccines.”
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 12, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck will let go of 58 people at its Rahway, New Jersey, headquarters effective Nov. 14. The layoffs come after Merck confirmed it will execute $3 billion in cost cuts to support the launches of more than 20 products nearing the market. The move could affect roughly 6,000 employees during the multi-year move. Merck is paring back its workforce to help support the launches of 20 products nearing the market, according to a July 29 announcement. The cuts include eliminating administrative, sales and research and development roles.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 4, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
Merck projected it could let go of about 6,000 employees as part of a multiyear process, affecting around 8% of its global workforce, as part of its recently announced cost-cutting initiative.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
August 1, 2025
Moderna
Layoffs
Cambridge, MA
1,001-5,000 employees
Moderna is downsizing its workforce by 10% globally to bring headcount to under 5,000 in “a difficult moment for the company,” CEO Stéphane Bancel told employees in a note July 31.
Disease Area: Antiviral, Immune Diseases, Multiple, Oncology, Rare Diseases
Drug Type: Biologic
July 30, 2025
Merck
Layoffs
Rahway, NJ
10,001-50,000 employees
During the company’s second quarter earnings report, Merck CEO Rob Davis said that the company was undergoing a $3 billion cut in spending, spread across administrative, sales and research and development roles. The savings amount to about $1.7 billion annually, hoping to hit the $3 billion mark by 2027.
Disease Area: Antiviral, Cardiology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule